A Holistic Phase Appropriate Strategy for HCP-Limits and HCP Characterization

Introduction During manufacturing of biopharmaceuticals prokaryotic and eukaryotic protein expression host systems like Escherichia coli (E. coli) and Chinese Hamster Ovary (CHO) cells generate a heterogeneous mixture of the desired therapeutic protein and a variety of endogenous host cell proteins ...

To read the full article and other articles in this issue, please register for a free account or log in.

We will not sell or give your information to a third party. See our Privacy Policy



Subscribe to our FREE newsletter

We will not sell or give your information to a third party. See our Privacy Policy